Enzyme.io Revenue and Competitors

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • Enzyme.io's estimated annual revenue is currently $2.5M per year.(i)
  • Enzyme.io's estimated revenue per employee is $101,500

Employee Data

  • Enzyme.io has 25 Employees.(i)
  • Enzyme.io grew their employee count by -32% last year.

Enzyme.io's People

NameTitleEmail/Phone
1
CEO & CofounderReveal Email/Phone
2
ControllerReveal Email/Phone
3
Managing Director ConsultingReveal Email/Phone
4
Chief Operating Officer & CofounderReveal Email/Phone
5
Director MarketingReveal Email/Phone
6
Director ProductReveal Email/Phone
7
Director Customer SuccessReveal Email/Phone
8
Director DesignReveal Email/Phone
9
Sr. Manager Education & TrainingReveal Email/Phone
10
Customer Success and Quality Solutions ManagerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$2.9M294%N/AN/A
#2
$43.4M2728%N/AN/A
#3
$14.1M9711%N/AN/A
#4
$1460M82917%$1.1BN/A
#5
$310M152720%N/AN/A
#6
$194.1M956-5%N/AN/A
#7
$223.9M1080-33%$101.6MN/A
#8
$581.3M27089%$253.1MN/A
#9
$716.2M35282%N/AN/A
#10
$801.4M394852%N/AN/A
Add Company

What Is Enzyme.io?

Enzyme's mission is to automate and simplify life science regulatory approval and compliance. We reduce your cost of compliance and help bring your cutting-edge technology to market faster. Our cloud based Quality Management System (QMS) streamlines documentation and integrates with tools you are already using. And our experts guide you through your entire regulatory and compliance lifecycle: from pre-submission, to product design and development, regulatory submission, and post-market compliance. Enzyme supports all life science companies, with an emphasis on companies making digital health, or software as a medical device (SaMD), products.

keywords:N/A

N/A

Total Funding

25

Number of Employees

$2.5M

Revenue (est)

-32%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Enzyme.io News

2022-04-19 - Angiotensin receptor blockers tied to less ventilation ...

... an angiotensin receptor blocker (ARB), 18% an angiotensin-converting enzyme (ACE) inhibitor and 64% neither an ARB nor ACE inhibitor.

2022-04-17 - Adverse Events with IO-TKI Combination Regimens for ...

Adverse Events with IO-TKI Combination Regimens for Advanced RCC and ... enzyme] inhibitor based on patient comorbidities, if possible.

2022-04-13 - Investing In Enzyme (MLN) – Everything You Need to Know

Securities.io is committed to rigorous editorial standards. We may receive compensation when you click on links to products we review.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$10.9M26-42%$499M
#2
$4.2M27-31%N/A
#3
$2.7M2856%N/A
#4
$6.5M28-15%N/A
#5
$6.5M28-15%N/A